Ab&B Bio Tech Co Ltd JS

Ab&B Bio Tech Co Ltd JS FCF/Debt

The Free Cash Flow to Debt Ratio of Ab&B Bio Tech Co Ltd JS (2627.HK) as of Oct 20, 2026 is -46.54 %. In the previous year, Free Cash Flow to Debt Ratio was -141.70 % — a change of -67.16% (higher).

FCF/Debt

-46.54 %

YoY

-67.16%

Last updated:

Free Cash Flow to Debt Ratio of Ab&B Bio Tech Co Ltd JS is 2024 -46.54 % . Free Cash Flow to Debt Ratio of Ab&B Bio Tech Co Ltd JS was 2023 -141.70 % . It decreases by -67.16% higher compared to the previous year.

The Ab&B Bio Tech Co Ltd JS FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2023
-141.70 CNY
Jan 1, 2024
-46.54 CNY
The Ab&B Bio Tech Co Ltd JS FCF/Debt history
YEARFCF/DebtYoY
-46.54 %-67.16%
-141.70 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ab&B Bio Tech Co Ltd JS Stock analysis

What does Ab&B Bio Tech Co Ltd JS do? Ab&B Bio Tech Co Ltd JS is a biotechnology company headquartered in Taizhou, China, operating within the healthcare sector. The company is engaged in the research, development, manufacturing, and commercialization of vaccines. It has a product pipeline featuring two core vaccine candidates: a quadrivalent subunit influenza vaccine and a lyophilized human rabies vaccine. Additionally, the company has 11 other vaccine candidates in its pipeline. Ab&B Bio Tech Co Ltd JS is listed on the Hong Kong Stock Exchange with ticker 2627.HK and ISIN CNE1000071P9. The company's initial public offering (IPO) is scheduled for August 8, 2025. Its website is http://www.abbbio.com/. The company primarily serves the domestic market in China. Ab&B Bio Tech Co Ltd JS is a China-based entity with operations focused on biotechnology within the healthcare industry. The company's activities are centered around vaccine development and commercialization, targeting both existing and emerging market needs within China. Ab&B Bio Tech Co Ltd JS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ab&B Bio Tech Co Ltd JS stock

Free Cash Flow to Debt Ratio of Ab&B Bio Tech Co Ltd JS is -46.54 % in 2024.

Free Cash Flow to Debt Ratio of Ab&B Bio Tech Co Ltd JS changed from -141.70 % to -46.54 %, representing a -67.16% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Ab&B Bio Tech Co Ltd JS since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Ab&B Bio Tech Co Ltd JS with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Ab&B Bio Tech Co Ltd JS

All Key Metrics — Ab&B Bio Tech Co Ltd JS